Results
Over median follow-up of 6.9 years, 18% of the 49,361 patients
developed a DNM, which correlated with an incidence rate 3.8 times that
of the general population. The most common malignancies were lung,
post-transplant lymphoproliferative disorder, and prostate. Risk was
most increased for female genital, tongue/throat, and renal cancers.
Male gender, older age, smoking history, and impaired renal function
were risk factors for developing DNM, whereas the use of MMF for
immunosuppression was protective. Cigarette use, increasing age, the use
of ATG for induction and calcineurin inhibitors for maintenance were
risk factors for cancer-specific mortality. The development of a DNM
increased the risk of death by 40% (p<0.001).